https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3214&f=G&l=50&d=PTXT&p=65&S1=20210831&OS=20210831&RS=20210831
Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA
The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation’s (NASDAQ:OMER) marketing application for narsoplimab for hematopoietic stem cell transplant-associated…
